Literature DB >> 11861686

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.

O L Lopez1, J T Becker, S Wisniewski, J Saxton, D I Kaufer, S T DeKosky.   

Abstract

OBJECTIVE: To describe the effect of cholinesterase inhibitors (CEIs) on the natural course of Alzheimer's disease (AD).
METHODS: The short and long term effects of CEIs were evaluated in 135 patients with probable Alzheimer's disease relative to 135 patients who were never exposed to CEIs matched by age, education, duration of the symptoms, and cognitive status. We measured 1 year change in cognitive and functional performance, and the likelihood of arriving at each of four end points: (1) mini mental state examination (MMSE) of 9 or lower, (2) Blessed dementia rating scale for activities of daily living of 12 or higher, (3) nursing home admission, and (4) death, over an average 3 years of observation (36.7 (SD 21.5) months).
RESULTS: Patients on CEIs were better cognitively and functionally after 1 year compared with those patients who never used CEIs. A proportional hazard analysis with CEI use as a time dependent covariate showed that the use of CEIs decreased the risk of nursing home admission. There was no association, however, between use of CEIs and time to cognitive and functional end points, or to death.
CONCLUSIONS: This observational study showed that there was an initial cognitive and functional benefit from the use of CEIs in Alzheimer's disease, which waned as the disease progressed. However, the results suggest that there is a long term beneficial effect of the use of CEIs, as indicated by the delay in admission to nursing homes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861686      PMCID: PMC1737770          DOI: 10.1136/jnnp.72.3.310

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  29 in total

1.  Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II.

Authors:  O L Lopez; J T Becker; W Klunk; J Saxton; R L Hamilton; D I Kaufer; R A Sweet; C Cidis Meltzer; S Wisniewski; M I Kamboh; S T DeKosky
Journal:  Neurology       Date:  2000-12-26       Impact factor: 9.910

2.  Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I.

Authors:  O L Lopez; J T Becker; W Klunk; J Saxton; R L Hamilton; D I Kaufer; R A Sweet; C Cidis Meltzer; S Wisniewski; M I Kamboh; S T DeKosky
Journal:  Neurology       Date:  2000-12-26       Impact factor: 9.910

3.  Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.

Authors:  R S Doody; D S Geldmacher; B Gordon; C A Perdomo; R D Pratt
Journal:  Arch Neurol       Date:  2001-03

4.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study.

Authors:  S L Rogers; R S Doody; R D Pratt; J R Ieni
Journal:  Eur Neuropsychopharmacol       Date:  2000-05       Impact factor: 4.600

5.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

Authors:  B Winblad; K Engedal; H Soininen; F Verhey; G Waldemar; A Wimo; A L Wetterholm; R Zhang; A Haglund; P Subbiah
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

8.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

Authors:  R C Mohs; R S Doody; J C Morris; J R Ieni; S L Rogers; C A Perdomo; R D Pratt
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

9.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

10.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06
View more
  61 in total

1.  Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.

Authors:  P McNamee; A Vanoli; D Hutchings; I McKeith; J Bond
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  [Efficacy of caregiver support groups for dementia].

Authors:  A Kurz; J Hallauer; S Jansen; J Diehl
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

3.  Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Authors:  Jaime Caro; Maribel Salas; Alexandra Ward; Denis Getsios; Kristen Migliaccio-Walle; Frances Garfield
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.

Authors:  Michelle M Mielke; Jeannie-Marie Leoutsakos; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; JoAnn T Tschanz; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

5.  Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.

Authors:  Marta Ibarria; Montserrat Alegret; Sergi Valero; Amèrica Morera; Marina Guitart; Pilar Cañabate; Mariola Moreno; Susana Lara; Susana Diego; Joan Hernández; Natàlia Tantinyá; Maribel Vera; Isabel Hernández; James T Becker; Agustín Ruíz; Mercè Boada; Lluís Tárraga
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

6.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease.

Authors:  I Masse; R Bordet; D Deplanque; A Al Khedr; F Richard; C Libersa; F Pasquier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

7.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Nick Bosanquet; Andrew Yeates
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 9.  Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?

Authors:  Ben Seltzer
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.

Authors:  Daniel D Christensen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.